Try
Tarsus Pharmaceuticals, Inc.
TARSUnited States
26 filed reports · 432 financial concepts · 1 earnings calls · 0 media appearances
Filed reports
26 reports · Sep 2020 to Jun 2026Each report counts once it has at least one extracted financial fact. Also extracted from these reports: 2 guidance figures.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 18 | 3,545 | Sep 2020 to Jun 2026 |
| Annual · 10-KSEC EDGAR | 6 | 2,786 | Dec 2020 to Dec 2025 |
| Current · 8-KSEC EDGAR | 2 | 4 | Dec 2024 to Mar 2026 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2026 Q2 | 10-Q | Jun 30, 2026 | Aug 6, 2026 | 449 | Open |
| FY2026 Q1 | 10-Q | Mar 31, 2026 | May 6, 2026 | 266 | Open |
| FY2026 Q1 | 8-K | Mar 31, 2026 | May 6, 2026 | 2 | Open |
| FY2025 | 10-K | Dec 31, 2025 | Feb 23, 2026 | 912 | Open |
| FY2025 Q3 | 10-Q | Sep 30, 2025 | Nov 4, 2025 | 303 | Open |
| FY2025 Q2 | 10-Q | Jun 30, 2025 | Aug 6, 2025 | 191 | Open |
| FY2025 Q1 | 10-Q | Mar 31, 2025 | May 1, 2025 | 193 | Open |
| FY2024 | 10-K | Dec 31, 2024 | Feb 25, 2025 | 470 | Open |
| FY2024 Q4 | 8-K | Dec 31, 2024 | Feb 25, 2025 | 2 | Open |
| FY2024 Q3 | 10-Q | Sep 30, 2024 | Nov 13, 2024 | 199 | Open |
| FY2024 Q2 | 10-Q | Jun 30, 2024 | Aug 8, 2024 | 176 | Open |
| FY2024 Q1 | 10-Q | Mar 31, 2024 | May 8, 2024 | 185 | Open |
Financial data
432 concepts · 6,335 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial412 concepts · 5,998 facts · Dec 2018 to Jul 2026
- Stockholders equity (US GAAP)39 · Dec 2018 to Jun 2026
- Adjustments to additional paid in capital sharebased compensation requisite service period recognition value38 · Dec 2018 to Jun 2026
- Net income loss38 · Dec 2018 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents37 · Dec 2018 to Jun 2026
- Allocated share based compensation expense35 · Sep 2019 to Jun 2026
- Cash and cash equivalents at carrying value35 · Sep 2019 to Jun 2026
- Comprehensive income net of tax35 · Sep 2019 to Jun 2026
- Depreciation35 · Sep 2019 to Jun 2026
- Nonoperating income expense35 · Sep 2019 to Jun 2026
- Operating income loss35 · Sep 2019 to Jun 2026
- Operating lease cost35 · Sep 2019 to Jun 2026
- Research and development expense35 · Sep 2019 to Jun 2026
- Capital expenditures incurred but not yet paid34 · Dec 2019 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents period increase decrease including exchange rate effect34 · Dec 2019 to Jun 2026
- Increase decrease in employee related liabilities34 · Dec 2019 to Jun 2026
- Increase decrease in other accounts payable and accrued liabilities34 · Dec 2019 to Jun 2026
- Increase decrease in other noncurrent assets34 · Dec 2019 to Jun 2026
- Increase decrease in other receivables34 · Dec 2019 to Jun 2026
- Net cash provided by used in financing activities34 · Dec 2019 to Jun 2026
- Net cash provided by used in investing activities34 · Dec 2019 to Jun 2026
- Net cash provided by used in operating activities34 · Dec 2019 to Jun 2026
- Payments to acquire property plant and equipment34 · Dec 2019 to Jun 2026
- Share based compensation34 · Dec 2019 to Jun 2026
- Operating lease liability33 · Sep 2020 to Jun 2026
Segment14 concepts · 201 facts · Dec 2022 to Jun 2026
- Revenue44 · Dec 2022 to Jun 2026
- Cost of goods and services sold (US GAAP)15 · Dec 2022 to Jun 2026
- Costs and expenses14 · Dec 2022 to Jun 2026
- Depreciation depletion and amortization14 · Dec 2022 to Jun 2026
- Interest expense nonoperating14 · Dec 2022 to Jun 2026
- Interest income other14 · Dec 2022 to Jun 2026
- Net income loss14 · Dec 2022 to Jun 2026
- Operating income loss14 · Dec 2022 to Jun 2026
- Research and development expense14 · Dec 2022 to Jun 2026
- Segment reporting other item amount14 · Dec 2022 to Jun 2026
- Selling and marketing expense (US GAAP)14 · Dec 2022 to Jun 2026
- Selling general and administrative expense8 · Mar 2024 to Jun 2026
- General and administrative expense (US GAAP)4 · Dec 2022 to Dec 2025
- Income tax expense benefit4 · Mar 2025 to Jun 2026
Product4 concepts · 130 facts · Mar 2020 to Jun 2026
- Revenue81 · Mar 2020 to Jun 2026
- Cost of goods and services sold (US GAAP)23 · Sep 2022 to Dec 2025
- Elanco15 · Dec 2024 to Jun 2026
- Cost of revenue (US GAAP)11 · Mar 2020 to Dec 2022
KPI1 concepts · 4 facts · Dec 2024 to Dec 2025
- Deliveries4 · Dec 2024 to Dec 2025
Guidance1 concepts · 2 facts · May 2026
- Revenue Guidance2 · May 2026
Segments
331 factsFigures broken down by business line, region, product or another axis the company reports on.
Statement business segments1 member · 201 facts
- Reportable201 · Dec 2022 to Jun 2026
Product or service9 members · 130 facts
- Product38 · Sep 2022 to Jun 2026
- License And Collaboration30 · Mar 2020 to Jun 2026
- License And Service15 · Mar 2020 to Dec 2022
- License And Collaboration Other11 · Sep 2022 to Sep 2024
- Collaboration9 · Mar 2020 to Sep 2022
- License Fees And Collaboration9 · Dec 2020 to Dec 2024
- Commercial Sales Milestone Payments8 · Dec 2024 to Jun 2026
- Event Based Development Milestone7 · Dec 2024 to Mar 2026
- Collaboration Revenue3 · Dec 2020 to Dec 2022
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
No commentary or risk-factor text for this company.
Earnings calls
1 calls · Aug 2026Transcripts with management claims and analyst questions, one per fiscal period.
- FY2026 Q2Aug 6, 2026
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.